



## Virbac announces close of acquisition of veterinary assets from Pfizer in Australia

CARROS, France – February 2, 2010

Virbac announces the successful closing on January 29th of its agreement with Pfizer Inc. to acquire certain veterinary products and related assets, including a manufacturing facility, in Australia. The agreement has been approved by the Australian Competition and Consumer Commission; it was part of the divestment required by the Commission in connection with Pfizer's recent acquisition of Wyeth, including its Fort Dodge Animal Health business. Virbac has acquired rights to a portfolio of livestock products historically marketed in Australia by Fort Dodge Animal Health for use in farm animals, primarily cattle and sheep. The portfolio includes parasiticides (80% of sales) and vaccines (20%) that achieved net sales of approximately 36 million Australian dollars in 2009. This new portfolio will perfectly fit and complement the current range of products that Virbac Australia is bringing to its customers.

### **VIRBAC : Passionate about Animal Health**

NYSE Euronext – Compartiment B / code ISIN : FR0000031577 / MNEMO : VIRP

Corporate Finance : tél. 33 4 92 08 71 32

E-mail : [finances@virbac.com](mailto:finances@virbac.com) – Site : [www.virbac.com](http://www.virbac.com)